Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly update

Abbott Laboratories has reported fresh quarterly figures and updated its outlook, keeping the focus on medical devices and diagnostics amid shifting healthcare demand. What the latest numbers reveal and why the stock remains closely watched by US investors.

Abbott Laboratories is back in the spotlight after releasing its latest quarterly results and updating guidance for 2025, giving investors fresh insights into trends in diagnostics, medical devices and nutrition. The company reported first?quarter 2025 numbers on 04/17/2025, including organic sales growth and margin trends, according to Abbott investor relations as of 04/17/2025. In addition, Abbott provided comments on demand for glucose monitoring systems and cardiovascular devices, which remain key growth drivers in the US market, as cited by Reuters as of 04/17/2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Medical technology, diagnostics, nutrition
• Headquarters/country: Abbott Park, Illinois, United States
• Core markets: United States, Europe, emerging markets
• Key revenue drivers: Medical devices, diagnostics, nutrition products, established pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare group with four major divisions: medical devices, diagnostics, nutrition and established pharmaceuticals. The company focuses on technologies that support chronic disease management, hospital diagnostics and everyday health. In medical devices, Abbott offers products for cardiovascular care, diabetes management and neuromodulation, targeting both hospitals and outpatient settings. These businesses generate a large share of revenue in the United States, one of the most important healthcare markets globally, according to Abbott corporate information as of 03/2025.

The diagnostics segment provides laboratory systems, point?of?care tests and rapid diagnostics used by hospitals, laboratories and clinics. Demand in this area is influenced by healthcare utilization, screening programs and reimbursement rules. Following the pandemic?driven spike in COVID?19 testing, Abbott has been transitioning toward more normalized diagnostic demand, offsetting declining COVID revenues with growth in core lab and molecular platforms, as highlighted around its full?year 2024 report published on 01/24/2025, according to Abbott investor relations as of 01/24/2025.

Nutrition is another pillar of Abbott’s business. The company sells infant formula, pediatric nutrition and adult nutrition products under established brands. This segment depends on birth rates, consumer confidence and competitive dynamics in retail channels. After supply?chain challenges in prior years, Abbott has worked to stabilize supply and restore brand positioning in key markets such as the US pediatric nutrition space, as referenced in management comments accompanying its 2024 annual results, according to Wall Street Journal company coverage as of 01/25/2025.

Main revenue and product drivers for Abbott Laboratories

One of the most closely watched product lines at Abbott is its continuous glucose monitoring system, marketed for people living with diabetes. This franchise sits within the medical devices segment and has delivered double?digit growth in recent years, driven by adoption in both type 1 and type 2 diabetes patients. During the first quarter of 2025, management reported continued strong demand for glucose monitoring, helping medical devices deliver reported sales growth compared with the prior?year quarter, according to Abbott investor relations as of 04/17/2025.

Cardiovascular and structural heart products also play a central role. Abbott offers devices for transcatheter procedures, cardiac rhythm management and heart failure monitoring. These devices benefit from aging populations and broader access to minimally invasive treatments, particularly in the United States, where hospital systems continue to invest in interventional cardiology. However, procedure volumes can be sensitive to macroeconomic conditions and hospital staffing levels, which can introduce volatility into quarterly results, as noted by sector commentary around Abbott’s 2024 performance, according to Bloomberg market data as of 01/26/2025.

On the diagnostics side, Abbott’s core lab instruments and test menus are often sold through long?term contracts with hospitals and reference laboratories. Revenue in this area tends to be recurring once installed, but can be affected by testing volumes and competition from other large diagnostics players. Following the unwinding of COVID?related testing sales, management has emphasized growth in non?COVID diagnostics, including immunoassays and molecular testing, in its first?quarter 2025 earnings commentary, according to Reuters as of 04/17/2025.

Industry trends and competitive position

Abbott Laboratories operates in a competitive landscape that includes large diversified healthcare groups and specialized medtech and diagnostics firms. In continuous glucose monitoring, the company faces rivalry from other major players seeking to capture long?term contracts with payers and healthcare systems. The broader diabetes technology market is expanding as guidelines and payers increasingly recognize the value of continuous monitoring in reducing complications, which supports unit growth but also fuels price competition, according to S&P Global Market Intelligence as of 12/10/2024.

In diagnostics, Abbott is one of several global suppliers of laboratory platforms and rapid tests used by hospitals and clinics worldwide. Market growth is influenced by demographic trends, infectious disease prevalence and the push for faster, more accurate testing. While COVID?19 testing has declined sharply from pandemic peaks, core diagnostics continue to benefit from chronic disease management and screening programs. This supports a more stable demand environment over the medium term, although capital spending cycles at hospitals can affect the timing of new instrument placements, as discussed in sector reviews following major diagnostics company earnings for 2024, according to Financial Times as of 02/05/2025.

Nutrition and established pharmaceuticals add diversification to Abbott’s portfolio but also come with their own competitive and regulatory dynamics. Infant formula is a tightly regulated market with high brand sensitivity among consumers, while established pharmaceuticals, particularly in emerging markets, are exposed to pricing pressures and local competition. By operating across these segments, Abbott spreads risk but must also manage complex regulatory requirements and supply chains across multiple regions, which can affect margins during periods of disruption, as noted by commentary around global supply chain challenges in 2024, according to AP News as of 11/18/2024.

Why Abbott Laboratories matters for US investors

For US investors, Abbott Laboratories represents exposure to the intersection of medical technology, diagnostics and consumer health. The company is listed on the New York Stock Exchange under the ticker ABT and is included in major US equity indices, making it a widely held name in mutual funds and exchange?traded funds. Its revenue base is geographically diversified but anchored by the United States, which remains one of its largest markets by sales, according to geographic breakdowns discussed in the 2024 annual report published on 01/24/2025, as cited by Abbott annual report as of 01/24/2025.

The stock can be sensitive to macroeconomic conditions, healthcare utilization trends and reimbursement decisions in the US. Changes in insurance coverage for diabetes technology, adjustments to Medicare reimbursement or shifts in hospital budgets can influence demand for Abbott’s devices and diagnostics. Additionally, regulatory approvals or safety updates from agencies such as the US Food and Drug Administration can have visible share?price effects when they impact key product lines, as seen in prior years when new device approvals or label expansions were announced, according to US FDA information as of 2024.

For diversified US equity portfolios, Abbott’s combination of medical devices, diagnostics and nutrition can offer a mix of growth and defensive characteristics. Device and diagnostics businesses are often more cyclical and driven by innovation cycles, while nutrition and established pharmaceuticals can provide steadier demand patterns. However, the balance between these segments can shift over time as the company invests more heavily in high?growth areas such as diabetes technology and structural heart devices, a trend highlighted in management’s capital allocation comments during recent earnings calls in 2024 and early 2025, according to Morningstar equity research summary as of 04/18/2025.

Conclusion

Abbott Laboratories remains a key player in the US and global healthcare markets, with recent quarterly results underscoring the importance of medical devices and diagnostics as growth engines while nutrition and established pharmaceuticals provide additional diversification. The company’s exposure to diabetes technology, cardiovascular care and core diagnostics ties its prospects closely to long?term health trends, innovation cycles and reimbursement decisions. For US investors, the stock offers a way to participate in structural growth in healthcare demand, but performance will depend on execution in high?growth product categories, regulatory developments and the ability to navigate competition and pricing pressures across its portfolio.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.